Dr. Jacqueline Lui, President of Eagle IP Limited, gave a lecture to the students of the course Commercialization of Biotechnology Products at the Department of Applied Biology and Chemical Technology of The Hong Kong Polytechnic University.

Our Past Events

Recommended Insights

China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

23 April 2020
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]

China Proposes New Examination Guidelines for Utility Models

24 November 2022
The Utility Model (UM) in China has always been a popular choice for patent filing due to its relatively low cost and speed of prosecution. The UM prosecution only includes a preliminary examination, which is essentially a mini (stripped down) version of an invention application’s substantive examination.1 With the simplified examination process, UMs are typically […]

How Smart is a "Skilled Person in the Art"?

11 April 2022
Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

10 January 2023
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]
Top crossarrow-right